Rachel Anhorn | Director, Payer Policy and Health Outcomes
Foundation Medicine Inc

Rachel Anhorn, Director, Payer Policy and Health Outcomes, Foundation Medicine Inc

Rachel is a Director of Payer Policy and Health Outcomes on the Payer Relations and Reimbursement Team at Foundation Medicine. She leads the development of US HEOR initiatives and is focused on payer education about the unique clinical value of  comprehensive genomic profiling. Her professional interests include helping shape healthcare policy to promote the value of oncology diagnostics and genomically-matched precision treatment to improve outcomes and cost effectiveness of cancer care for all stakeholders.
Previous to her role at Foundation Medicine she worked at Pfizer as a Field Medical Director in the Biosimilars group, at Boehringer Ingelheim as an Associate Director of Health Economics and Outcomes Research providing support for IPF, Oncology, COPD, Diabetes and Atrial Fibrillation, and as a Medical Sales Liaison (MSL) supporting the metabolic disease programs in endocrinology and nephrology. Rachel received her education through the Rutgers Post--Doctoral Fellowship--BMS  in Medical Strategy and Scientific Communications, her Doctor of Pharmacy at the University of Minnesota College of Pharmacy, and a Bachelor of Science, Biochemistry at the University of Wisconsin River Falls. 


Pharma Pricing & Market Access USA Day 1 @ 16:10

PANEL: The impact of precision medicine and biomarkers on drug pricing structures

  • Understanding how biomarkers will have an increasing role to play in drug pricing 
  • What impact will precision medicine have on the overall cost of healthcare
  • Do we have the necessary evidence to put a price on precision medicine?

back to speakers